Oral drug delivery systems continue to be one of the most widely used approaches in modern healthcare because of their convenience, accurate dosing, and patient acceptance. Among the various types of oral drug delivery system technologies, the oral solid dosage form has remained a preferred choice in the pharmaceutical industry for decades. However, traditional oral tablets are not always easy for every patient population to consume, especially paediatric, geriatric, and dysphagic patients who often experience difficulty swallowing conventional tablets, as highlighted in studies published by the National Centre for Biotechnology Information.1-3
To address these challenges, orodispersible tablets, also known as oral disintegrating tablets or fast disintegrating tablets, have emerged as an advanced approach in pharmaceutical formulation development. Unlike conventional tablets, orodispersible formulations are designed to rapidly disintegrate in the mouth without the need for water, improving convenience and supporting better medication adherence solutions. Research published in pharmaceutical studies has shown that orodispersible tablet technologies are increasingly being adopted because of their patient-friendly administration and improved compliance potential.2,4
In recent years, the pharmaceutical industry has also focused heavily on patient-centric formulation innovation. Modern orally disintegrating tablet technologies combine rapid disintegration properties, taste-masking approaches, and optimised excipient selection to create more advanced oral drug delivery systems that improve the overall medication experience for patients.5
Conventional tablets are among the most commonly used oral solid dosage form technologies in the pharmaceutical industry. These tablets are designed to be swallowed with water and disintegrate after reaching the stomach. Their manufacturing process, dosage accuracy, and long-term stability have made them a standard choice across multiple therapeutic categories.6
Orodispersible tablets (ODTs), are formulated to rapidly disintegrate in the mouth without requiring water. ODT formulations are specifically developed to improve patient convenience and support easier medicine administration, especially for paediatric, geriatric, and dysphagic patients.1-3
The difference between conventional tablets and ODT formulations is not limited to administration alone. Conventional tablets are primarily optimised for stability and controlled disintegration inside the gastrointestinal tract. In contrast, ODT formulations involve advanced pharmaceutical formulation development approaches using superdisintegrants, taste-masking technologies, and specialised excipients that allow rapid tablet dispersion while maintaining tablet strength and performance.7
As healthcare moves toward patient-centric treatment approaches, ODTs are becoming an increasingly important part of modern oral drug delivery systems. Their convenience, ease of administration, and potential role in medication adherence solutions are driving growing interest in ODT technologies across the pharmaceutical industry.1
The development of ODTs was largely driven by the growing need for more patient-friendly oral drug delivery systems. While conventional oral tablets remain widely used, several patient populations continue to face challenges with traditional oral solid dosage forms.
These challenges have strengthened the need for patient-friendly dosage forms such as ODTs, which can be administered without the need for swallowing intact tablets or modifying the original formulation.
ODT formulations are becoming an important part of patient-centric pharmaceutical innovation strategy within modern healthcare.
The increasing adoption of ODTs reflects the pharmaceutical industry's growing focus on patient-centric oral drug delivery systems. Compared to conventional oral tablets, ODT formulations offer several advantages that improve convenience, accessibility, and the overall medication experience.
Advanced formulation technologies such as super disintegrants play a critical role in achieving this performance.
The difference between conventional oral tablets and ODTs goes beyond administration convenience. Both dosage forms follow different pharmaceutical formulation development approaches based on how the medicine is intended to perform inside the body.
Conventional oral tablets are primarily designed to:
These formulations generally focus on mechanical strength, stability, and controlled disintegration performance within traditional oral drug delivery systems.
To achieve this rapid disintegration performance, ODTs often incorporate:
These formulation strategies help maintain tablet integrity while ensuring fast dispersion and improved patient acceptability.
One of the key formulation differences in orodispersible tablets is the use of super disintegrants. This ingredient rapidly absorbs saliva and promotes quick tablet breakdown inside the oral cavity.
Commonly used super disintegrants include:
These excipients play a critical role in improving the disintegration efficiency of ODT formulations.
Compared to conventional tablets, ODT formulations require more advanced pharmaceutical formulation development because they must balance multiple performance factors simultaneously.
Key formulation considerations include:
As a result, ODT technologies often involve advanced manufacturing approaches such as direct compression and freeze-drying techniques.
The pharmaceutical industry is increasingly moving toward patient-centric healthcare approaches, where convenience, accessibility, and treatment experience are becoming as important as therapeutic effectiveness.
Orodispersible tablets are gaining attention because they simplify medicine administration and improve patient convenience, particularly for paediatric, geriatric, and dysphagic patients.
Key factors driving the growth of ODT technologies include11:
Research studies have highlighted that patient-centric dosage forms such as ODT formulations can support better treatment acceptance and patient compliance. 11
The evolution of oral drug delivery systems reflects the pharmaceutical industry's growing focus on patient-centric healthcare and formulation innovation. While conventional oral tablets continue to remain an important oral solid dosage form, ODTs are increasingly shaping the future of convenient and accessible medicine administration.
From supporting patient compliance and ease of administration to advanced pharmaceutical formulation development approaches, ODT formulations offer several advantages that align with the changing expectations of modern healthcare. Their ability to support paediatric, geriatric, and dysphagic patients has positioned ODTs as an important advancement within next-generation oral drug delivery systems.
As pharmaceutical companies continue to invest in innovative and patient-friendly dosage forms, the focus on advanced ODT technologies is expected to grow further across global healthcare markets.
At NOVUMGEN, the emphasis on ODT technologies reflects a commitment toward advancing modern oral drug delivery systems through patient-centric pharmaceutical formulation development. By focusing on innovative ODT formulations, advanced manufacturing capabilities, and evolving healthcare needs, NOVUMGEN continues to contribute toward the broader shift from traditional medicine administration approaches to more accessible, convenient, and future-ready pharmaceutical solutions.